El Mansoura 1

This trial studies completely edentulous patients aged 45 to 70 years to compare three different impression methods used to create 3D-printed mandibular implant overdentures. The goal is to see how these techniques affect chewing efficiency and patient satisfaction. The study is a randomized crossover design where each patient receives two implants and tests all three impression techniques in different sequences. The three impression techniques being evaluated include: conventional open-tray implant-level impression using hydrocolloid and silicone materials, functionally generated reline impression involving an interim prosthesis and border molding, and mucostatic base with functional borders impression using intraoral scanning and digital 3D printing. Each overdenture is worn for three months, separated by two-week washout periods with a provisional denture. Participants will be monitored over 9 months with assessments of masticatory efficiency using a color-mixing ability test at 3, 6, and 9 months after overdenture insertion. Patient satisfaction will also be recorded using a Visual Analog Scale at the same intervals. The study includes regular follow-ups to evaluate functional outcomes and patient perceptions related to each impression technique.

Researchers are evaluating the safety and preliminary effectiveness of oral roflumilast in adults with moderate-to-severe plaque psoriasis over a 12-week period. This Phase 2 pilot study focuses on improving skin symptoms measured by the Psoriasis Area and Severity Index (PASI) and includes assessments of body mass index (BMI) and safety outcomes. The study includes both male and female adults who require systemic therapy for their psoriasis. Participants will receive oral roflumilast starting at a dose of 250 mcg once daily for the first 10 days. After this initial period, the dose will increase to 500 mcg once daily for the remaining weeks, continuing daily for a total of 12 weeks. There are no comparison groups, and all participants receive the same treatment. The study is open-label, meaning both researchers and participants know the treatment being given. During the study, participants will have scheduled visits to monitor their clinical response using the PASI score and to record changes in BMI. Safety will be closely observed by tracking any treatment-related side effects, serious adverse events, and laboratory test results. Data will be analyzed overall and separately for male and female participants. The total participation time is 12 weeks of treatment with ongoing safety and efficacy assessments throughout.

Researchers are evaluating intra-lesional immunotherapy using the measles-mumps-rubella (MMR) vaccine as a treatment for patients aged 10 to 60 years with recalcitrant tinea cruris and corporis. These patients have persistent fungal infections that have not improved despite standard antifungal treatments, including at least two courses of systemic antifungal therapy within the last three months. This pilot study aims to assess the safety and effectiveness of this new immunotherapy approach for difficult-to-treat tinea infections. Participants will receive injections of the MMR vaccine directly into the active borders of affected skin lesions every two weeks for a total of six weeks. If partial improvement is seen but the infection does not completely clear, the treatment may be extended for an additional six weeks, with up to six injection sessions in total. During the first two weeks, patients will also receive pulse itraconazole treatment. Clinical assessments will be made at each visit to monitor the extent of skin involvement and symptoms such as itching. Throughout the study, researchers will carefully observe participants for safety, including any injection site reactions, fever, initial worsening of lesions, or rare allergic reactions. The affected body surface area will be measured at every visit, which occur every two weeks, up to six weeks or up to twelve weeks if treatment is extended. This close monitoring will help evaluate the treatment's impact and potential side effects over the full study duration.

Researchers are evaluating and comparing the accuracy of three different methods for taking impressions to create full-arch implant-supported dental prostheses. The study involves participants who have four dental implants in their lower jaw and aims to find out which impression technique provides the most precise fit. Accurate impressions are important to ensure that the final prosthetic framework fits well, which supports long-term implant success and comfort. The three impression techniques tested are conventional splinted impressions using polyvinyl siloxane (PVS) material, standard digital impressions with an intraoral scanner, and geometric pattern-assisted digital impressions that use a visual reference pattern to improve scanning accuracy. Each participant undergoes all three methods in a randomized order. Digital models are created from each impression, and prosthetic frameworks are designed and made using computer-aided design and manufacturing (CAD/CAM) technology and 3D laser sintering. During the study, participants receive each impression type at different times, and the accuracy is measured immediately after each session by comparing 3D deviations between test and reference scans using digital superimposition software. Clinical passivity is also checked using a one-screw test to detect any misfits between the prosthesis and implants. The study includes assessments of oral health, monitoring for any issues, and requires participants to attend all scheduled appointments to evaluate the feasibility and precision of these advanced digital impression techniques over the entire study period.

Researchers are investigating the use of activated charcoal as a treatment for managing high phosphate levels, a common issue in patients with end-stage renal disease (ESRD) undergoing dialysis. Elevated phosphate can contribute to worsening vascular calcification, and current management typically involves limiting dietary phosphorus and using phosphate binders. This Phase 2 study explores activated charcoal, which may be better tolerated than conventional phosphate binders, as a potential alternative treatment in these patients. Participants will receive either oral activated charcoal capsules or standard phosphate binders, which include calcium-based or non-calcium-based (sevelamer) options. The study focuses on patients who have been on stable maintenance hemodialysis three times per week for at least six months. Treatments are given according to established protocols from kidney disease guidelines, and the study aims to assess the effects of activated charcoal on mineral and bone disorder related to chronic kidney disease. During the study, researchers will monitor serum phosphorus levels over an 8-week period to measure treatment impact. Participants will undergo regular evaluations consistent with kidney disease management, including assessments of mineral and bone disorder. Safety and efficacy of the treatments will be observed, contributing important information about alternative phosphate management options in chronic kidney disease patients. Total study participation duration and additional follow-up details are based on the study protocol.

Inflammatory Bowel Diseases (IBD), including Crohn's disease and ulcerative colitis (UC), are complex and ongoing inflammatory conditions that cause severe symptoms like diarrhea, abdominal pain, weight loss, and chronic fatigue. These symptoms can lead to serious, life-threatening complications. The disease develops through a breakdown of the intestinal barrier, which allows bacteria to trigger strong immune responses and inflammation in the intestines. This research is focused on studying how the drug dapagliflozin may help by activating autophagy and suppressing cell death, potentially easing IBD symptoms. The study compares the effects of dapagliflozin, a drug typically used to manage type-2 diabetes and heart failure, with mesalamine, a common treatment for mild to moderate ulcerative colitis that helps maintain remission. Participants will receive these treatments to assess their impact on disease activity. This trial includes patients with mild to moderate UC confirmed by endoscopy and aims to evaluate treatment effects over six months. During the study, the primary outcome measured is the change in the Mayo score, which assesses UC severity, at six months. Participants will be monitored for symptoms and side effects, with regular assessments to track disease progress and treatment response. The study enrolls adults aged 18 to 60 years and includes both men and women. Safety and effectiveness of the treatments will be closely observed throughout the trial period.

This research aims to evaluate and compare the effects of acupuncture and transcutaneous electrical nerve stimulation (TENS) on pain reduction after upper abdominal surgeries, specifically laparoscopic cholecystectomy and gastrectomy. The study focuses on minimizing postoperative pain, which results from tissue damage during surgery and leads to acute pain signals sent to the brain. The goal is to provide guidance on the effectiveness and safety of these physical therapy approaches in managing post-surgical pain. Participants will receive either acupuncture or TENS after their upper abdominal surgery. Acupuncture involves inserting sterile needles at specific body points shortly after surgery and continuing daily sessions for five days in cases of gastrectomy. TENS treatment is applied using a device that delivers electrical stimulation up to 48 hours after surgery, with patients adjusting the intensity for pain relief. Both groups may also receive standard pain medications such as analgesics and nonsteroidal anti-inflammatory drugs. During the study, researchers will monitor participants' pain levels and assess their recovery quality at the start and four weeks after surgery. Patients will be observed for up to 48 hours or until discharge for physical therapy effects. The study includes evaluations of safety and tolerability, with participants undergoing regular assessments to measure pain changes and overall recovery progress.

Researchers are evaluating the clinical outcomes of two medications, dapagliflozin and acetazolamide, in adults hospitalized with acute heart failure. This study aims to compare how well these drugs improve the body's fluid balance and reduce hospital stay length when added to standard loop diuretic therapy. The trial also assesses the safety of these treatments to better understand their potential roles in managing acute heart failure. Participants will receive either dapagliflozin 10 mg, a sodium-glucose cotransporter-2 inhibitor, or acetazolamide 500 mg, a carbonic anhydrase inhibitor, alongside their usual IV loop diuretic treatment. The study focuses on the early period after hospital admission, with randomization occurring within 24 hours. Both drugs are being studied to see how they affect symptoms and fluid removal during the hospitalization. During the study, researchers will measure participants' breathlessness using a visual scale from the start to day 3, among other clinical assessments. Participants must be adults hospitalized for fluid overload due to acute heart failure and will be monitored for kidney function and other safety markers. The study ensures close observation of drug effects and side effects throughout the hospital stay to provide detailed information on treatment impact and safety.

Chronic Obstructive Pulmonary Disease (COPD) is a lung condition marked by ongoing respiratory symptoms like breathlessness, cough, and sputum production, caused by airway and alveoli abnormalities leading to persistent airflow blockage. COPD diagnosis is confirmed by spirometry showing non-fully reversible airflow obstruction. The disease involves inflammation characterized by specific immune cells and proteins, differing from asthma but sometimes overlapping with similar inflammatory patterns. This trial explores the connection between atopy and the frequency of COPD exacerbations, addressing uncertainties about atopy's role in COPD development and progression. Participants will undergo diagnostic tests including a Skin Prick Test for common allergens such as pollen, dust mites, pet dander, and mold. Blood tests will measure total serum IgE levels and peripheral blood eosinophil counts. The study also includes a quality of life assessment using the COPD Assessment Test (CAT). These tests aim to identify markers of allergic response and inflammation potentially linked to COPD exacerbations. Throughout the study, participants will be evaluated for atopy presence and monitored for COPD exacerbation frequency over periods of 2 and 6 months. Assessments include blood eosinophil counts and quality of life surveys. The study focuses on adults aged 40 to 70 diagnosed with COPD and excludes those with prior allergic diseases or other serious respiratory or systemic conditions. This comprehensive monitoring will help clarify the relationship between atopy and COPD symptoms.

This research aims to improve understanding of rare autoinflammatory diseases (AID), which cause repeated inflammatory episodes without infection or cancer. The study focuses on hereditary periodic syndromes (monogenic AID) caused by gene mutations, as well as related polygenic or multifactorial AID like Behcet's disease, Still disease, Schnitzler's disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, spondyloarthritis, and Castleman disease. The goal is to gather detailed clinical and therapeutic data to expand knowledge of these rare conditions, which are often difficult to diagnose outside specialized centers. Participants will be enrolled in the AIDA international registry, which uses a secure online platform to collect retrospective and prospective information. Data collected include demographics, genetics, clinical features, laboratory and radiologic results, treatments, and socioeconomic impact. The registry covers multiple specific AID types and will track patients over at least 10 years through routine clinical visits usually every 3-6 months. The platform supports data sharing and analysis to identify disease patterns, treatment responses, and long-term outcomes. During the study, patients' medical records will be regularly updated with clinical and laboratory data. Researchers will analyze changes in patient numbers and disease characteristics over time. The registry also aims to foster international collaboration, improve early diagnosis, assess quality of life and socioeconomic effects, and support future research and clinical trials. Patient data privacy is maintained by using pseudonyms and complying with data protection laws throughout the study.